Adenocarcinoma treatment cost in Israel typically involves a diagnostic phase with a PET-CT scan priced between $1,400 and $1,900, followed by specialized care. Primary surgical interventions such as a robotic da Vinci prostatectomy range from $24,600 to $38,500, while advanced options like HIPEC run from $61,200 to $95,900. Total expenses depend on the affected organ, cancer stage, and hospital type. Patients often find 30-50% savings compared to the US. Top destinations include Tel Aviv, Jerusalem, and Haifa.
Typical Adenocarcinoma Treatment Costs in Israel
Bookimed Expert Insight: Patients with complex gastrointestinal cases benefit from multidisciplinary teams at JCI-accredited centers like Sourasky. Specialists there, such as Dr. Ron Greenberg, integrate HIPEC with advanced surgery for a 90% oncology success rate. For those seeking private care, Assuta Medical Center allows patients to select their specific senior surgeon. Hadassah is ideal for cases requiring Nobel Prize-level research and AI-driven robotic technologies.
| Izrael | Turcja | Austria | |
| Zogniskowana ablacja ultradźwiękowa (HIFU) | od $15,200 | od $4,000 | od $12,000 |
| Terapia protonowa | od $48,000 | od $70,000 | od $80,000 |
| Prostatektomia z użyciem robota Da Vinci | od $24,570 | od $17,000 | od $20,000 |
| Procedura Whipple’a | od $38,500 | od $23,000 | od $45,000 |
| Operacja raka płuc | od $27,500 | od $17,000 | od $42,000 |
Kierownik Oddziału Onkologii Tkanek Miękkich i Kości w Centrum Medycznym Sourasky – dr Merimsky specjalizuje się w leczeniu złożonych przypadków mięsaków.
Dr Pelles Sharon specjalizuje się w zaawansowanych metodach leczenia gruczolakoraka w Centrum Medycznym Sourasky, w tym w chemioterapii HIPEC i immunoterapii.
Dr Sarid specjalizuje się w chemioterapii i radioterapii, posiadając ponad 25-letnie doświadczenie onkologiczne zdobyte w czołowym izraelskim Centrum Medycznym Sourasky (Ichilov).
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.